Silver Book Fact

The use of imatinib (Gleevec) has increased the eight-year survival rate for early chronic-phase myelogenous leukemia from 65% to 84%.

Romley, John A., Yuri Sanchez, John R. Penrod, Dana P. Goldman. Survery Results Show That Adults Are Willing To Pay Higher Insurance Premiums For Generous Coverage Of Specialty Drugs. Health Affairs. 2012; 31(4): 683-690

Reference

Title
Survery Results Show That Adults Are Willing To Pay Higher Insurance Premiums For Generous Coverage Of Specialty Drugs
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2012
Authors
Romley, John A., Yuri Sanchez, John R. Penrod, Dana P. Goldman
Volume & Issue
Volume 31, Issue 4
Pages
683-690

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient.   
  • Approximately one third of men diagnosed with prostate cancer will opt for surgical treatment.  
  • Between August 2004 and July 2014, the FDA approved: Six new anticancer therapeutics Five new uses for previously approved anticancer therapeutics Two new uses for imaging agents One new use for a screening test  
  • Improvements in surgical techniques and combination therapies increased the 1-year survival rate for lung cancer from 34 percent in 1975-1977 to 45 percent in 2006-2009.  
  • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in the pipeline would inhibit production of a protein that may interfere with the effectiveness of chemotherapy.